دورية أكاديمية
Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
| العنوان: | Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population. |
|---|---|
| المؤلفون: | Chehade R; Faculty of Medicine, Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.; Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada., Nofech-Mozes S; Precision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Plotkin A; Precision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Fan KY; Faculty of Medicine, University of Toronto, Toronto, ON, Canada., Das S; Faculty of Medicine, Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.; Division of Neurosurgery, St Michael's Hospital, Toronto, ON, Canada., Sahgal A; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Moravan V; VM Stats, Toronto, ON, Canada., Jerzak KJ; Faculty of Medicine, Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.; Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. |
| المصدر: | JCO precision oncology [JCO Precis Oncol] 2024 Mar; Vol. 8, pp. e2300487. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2017]- |
| مواضيع طبية MeSH: | Brain Neoplasms*/drug therapy , Brain Neoplasms*/secondary , Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Receptor, ErbB-2* , Molecular Targeted Therapy*, Female ; Humans ; In Situ Hybridization, Fluorescence/methods ; Retrospective Studies |
| مستخلص: | Purpose: Trastuzumab deruxtecan is a new treatment option for patients with advanced human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC). Although HER2-low status has been characterized in early and advanced BC, it has yet to be fully characterized in brain metastases (BrM). Methods: Patients who underwent surgery for BC BrM at Sunnybrook Health Sciences Centre and for whom HER2 status was available on resected BrM were studied. Estrogen receptor, progesterone receptor, and HER2 status were assessed on the basis of ASCO/College of American Pathologists (CAP) guidelines. HER2-zero was defined as immunohistochemistry (IHC) 0; HER2-low was defined as IHC 1+ or IHC 2+ with fluorescence in situ hybridization (FISH)-negative status. HER2-positive (HER2+) was defined as IHC 3+ or IHC 2+ with positive FISH. Clinicopathologic features were recorded. We also assessed the prognostic association between extent of HER2 expression and (1) brain-specific progression-free survival (bsPFS), as well as (2) overall survival (OS). Results: In this retrospective cohort of 102 patients with resected BC BrM, 53% (n = 54) were HER2+, 29.4% (n = 30) were HER2-low, and 17.6% (n = 18) had HER2-zero status. Among BrM that were triple-negative on the basis of ASCO/CAP guidelines, 63.6% (n = 14/22) were reclassified as being HER2-low. Sixty percent (n = 15/25) of BrM that were hormone receptor-positive/HER2-negative (HR+/HER2-) were reclassified as being HER2-low. In total, 51 patients had matched primary breast and BrM tissue available; results of HER2 status when categorized as HER2-zero, HER2-low, and HER2+ were concordant in 82.3% (n = 42/51) of cases (Cohen's kappa, 0.58; P = .07). There was no significant association between HER2-zero, HER2-low, and HER2+ status in BrM and either bsPFS or OS. Conclusion: Among patients with surgically resected BrM, a high proportion of those with metastatic triple-negative BC and HR+/HER2- disease have HER2-low BrM with potential to benefit from HER2-targeted therapy. |
| References: | Neuro Oncol. 2020 Aug 17;22(8):1173-1181. (PMID: 31970416) Int J Clin Oncol. 2022 Feb;27(2):332-339. (PMID: 34661778) NPJ Breast Cancer. 2023 Oct 23;9(1):86. (PMID: 37867174) Clin Breast Cancer. 2020 Feb;20(1):e54-e64. (PMID: 31447286) Eur Radiol. 2024 Feb;34(2):899-913. (PMID: 37597033) Nat Med. 2022 Sep;28(9):1840-1847. (PMID: 35941372) J Clin Oncol. 2020 Jun 10;38(17):1887-1896. (PMID: 32058843) NPJ Breast Cancer. 2021 Jan 4;7(1):1. (PMID: 33397968) Neuro Oncol. 2023 Jan 5;25(1):157-166. (PMID: 35639825) NPJ Breast Cancer. 2022 Dec 30;8(1):135. (PMID: 36585415) NPJ Breast Cancer. 2022 May 20;8(1):66. (PMID: 35595761) N Engl J Med. 2020 Feb 13;382(7):597-609. (PMID: 31825569) Neurooncol Adv. 2022 Sep 30;4(1):vdac154. (PMID: 36299795) NPJ Breast Cancer. 2023 Oct 11;9(1):82. (PMID: 37821514) Eur J Cancer. 2022 Mar;163:35-43. (PMID: 35032815) Oncologist. 2021 Nov;26(11):e1951-e1961. (PMID: 34506676) JAMA Oncol. 2022 Apr 01;8(4):1-4. (PMID: 35113160) Radiology. 2023 Aug;308(2):e222646. (PMID: 37526540) Neuro Oncol. 2021 Jun 1;23(6):894-904. (PMID: 33367836) Curr Treat Options Oncol. 2023 May;24(5):468-478. (PMID: 36971965) JAMA Netw Open. 2022 Aug 1;5(8):e2225424. (PMID: 35960523) N Engl J Med. 2022 Mar 24;386(12):1143-1154. (PMID: 35320644) ESMO Open. 2023 Aug;8(4):101615. (PMID: 37562195) J Clin Oncol. 2020 Jun 10;38(17):1951-1962. (PMID: 32330069) Nat Commun. 2023 Nov 18;14(1):7496. (PMID: 37980405) Neurooncol Adv. 2020 Dec 22;3(1):vdaa178. (PMID: 33585818) N Engl J Med. 2022 Jul 7;387(1):9-20. (PMID: 35665782) |
| المشرفين على المادة: | EC 2.7.10.1 (ERBB2 protein, human) EC 2.7.10.1 (Receptor, ErbB-2) |
| تواريخ الأحداث: | Date Created: 20240328 Date Completed: 20240401 Latest Revision: 20240406 |
| رمز التحديث: | 20240406 |
| مُعرف محوري في PubMed: | PMC10994430 |
| DOI: | 10.1200/PO.23.00487 |
| PMID: | 38547418 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2473-4284 |
|---|---|
| DOI: | 10.1200/PO.23.00487 |